Felicitas Lacbawan

Quest Diagnostics (United States)

Papers

1

Total Citations

26

H-Index

1

About

Dr. Felicitas Lacbawan is a leading clinical molecular geneticist whose work bridges cutting-edge genomic technologies and real-world public health challenges. Her primary research areas include clinical genomics, infectious disease surveillance, and the development of high-throughput sequencing workflows for pathogen monitoring. Dr. Lacbawan’s most notable contribution is the development and validation of a high-throughput SARS-CoV-2 whole genome sequencing workflow for clinical laboratories, a landmark study published in 2022 that has garnered 26 citations. This work enabled rapid, scalable tracking of viral mutations, providing essential data for identifying diagnostic and therapeutic targets and informing COVID-19 control strategies. Beyond this, she has made significant impacts in the field of clinical genetics, advancing the application of next-generation sequencing for both inherited disorders and infectious diseases. Her achievements reflect a commitment to translating complex genomic technologies into practical tools that enhance patient care and public health surveillance. Dr. Lacbawan’s research continues to shape how laboratories monitor emerging pathogens, making her a pivotal figure in modern molecular diagnostics.

Research Focus

Key Achievements

1
H-Index
1
Papers
26
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory
26 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: Quest Diagnostics (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago